Bionano Q4 revenue $8.2M (+30% YoY); FY2022 rev $27.8M (+55%)

Bionano Genomics, Inc.

Q4 revenue $8.2M, up 30% from Q4 2021; FY2022 revenue $27.8M, up 55% from FY2021.
Installed base of Saphyr systems reached 240 at YE 2022, a 46% increase over 2021.
Acquired Purigen Biosystems to accelerate OGM adoption; deal value not disclosed.
Achieved all 2022 ELEVATE! milestones; next-gen OGM system commercial launch planned H1 2023.
2023 revenue outlook provided but specific guidance range not included in this excerpt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bionano Genomics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $8.2 million.

Period: fourth quarter and fiscal year ended December 31, 2022
Revenue: $8.2 million
Result: reported results

Exact text from the filing

Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Genomics Reports Fourth Quarter and Full Year 2022 Results and Provides Revenue Outlook for 2023 • Q4 revenue was $8.2 million , which represents a 30% increase over Q4 2021 • 2022 revenue was $27.8 million , which represents a 55% increase over year end 2021 • Reached installed base of 240 Saphyr®

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bionano Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $27.8 million.

Period: fourth quarter and full year ended December 31, 2022
Revenue: $27.8 million
Result: reported results

Exact text from the filing

Full year 2022 revenue was $27.8 million , an increase of 55% compared to 2021.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.